Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Castle Biosciences (NASDAQ:CSTL) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Castle Biosciences beat estimated earnings by 81.0%, reporting an EPS of $-0.1 versus an estimate of $-0.54.
Revenue was up $27.78 million from the same period last year.
Last quarter the company beat on EPS by $0.5 which was followed by a 8.0% increase in the share price the next day.
Here's a look at Castle Biosciences's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.76 | -1.01 | -0.89 | -0.84 |
EPS Actual | -0.26 | -0.70 | -1.10 | -0.78 |
Revenue Estimate | 48.52M | 43.51M | 37.37M | 37.16M |
Revenue Actual | 61.49M | 50.14M | 42.04M | 38.34M |
To track all earnings releases for Castle Biosciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CSTL